The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers
Latest Information Update: 25 Jul 2023
At a glance
- Drugs Dilmapimod (Primary) ; Prednisolone
- Indications Asthma; Chronic obstructive pulmonary disease; Inflammation
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 27 Sep 2012 New trial record
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.